A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we rep...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, Judith Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stéphanie Héon, Keith D. Wilner, James G. Christensen, Michel J. Eck, Kwok‐Kin Wong, Neal I. Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne
التنسيق: Artigo
اللغة:الإنجليزية
منشور في: 2011
الوصول للمادة أونلاين:https://doi.org/10.1158/0008-5472.can-11-1340
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

https://doi.org/10.1158/0008-5472.can-11-1340

مواد مشابهة